Roquefort Therapeutics plc (ROQAF) Discusses Acquisition Of Coiled Therapeutics Call

Operator

Good afternoon, and welcome to the Roquefort Therapeutics acquisition of Coiled Therapeutics presentation. Today, we are joined by Stephen West, Executive Chairman; Edward Painter, Chairman and CEO of A2A Pharma; and Sridhar Vempati, Chief Strategy Officer and Executive VP of R&D of A2A Pharma. [Operator Instructions] I’ll now hand over to Stephen to begin the presentation. Thank you.

Stephen West
Executive Chairman

Great. Thanks, Harry. Welcome, everyone. Thanks for joining us today. As Harry outlined, we’re here to talk about the acquisition of Coiled Therapeutics, which is a transformational acquisition for us. My name is Stephen West. I’m Executive Chairman of Roquefort. So I’ll be giving a bit of an introduction to the transaction outlining the reasons behind why we’re doing it, why we think it’s very exciting for us and also very exciting for A2A.

And I’m pleased to advise that I am joined here by Ed Painter and Sridhar Vempati from A2A today as well. And they can go into a lot more detail about the science and the massive potential of the therapy that they have within Coiled Therapeutics.

Next slide. So just a few sort of bites on why we’re doing this presentation and why it’s so exciting. So back in March this year, we did signal to the market that we were pivoting away from being a preclinical stage company into being a clinical stage company. And by acquiring Coiled Therapeutics, we’re achieving this new strategic shift for the company. We are looking at acquiring Coiled Therapeutics for GBP 30 million. It’s going to be payable in Roquefort shares. So it is a reverse takeover transaction.